- Home
- HLXC vs PLX Comparison
HLXC vs PLX Comparison
Compare HLXC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$2.95
Company Overview
Basic Information| Metric | HLXC | PLX |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.2M | 207.1M |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HLXC | PLX |
|---|---|---|
| Price | $10.27 | $2.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 56.5K | ★ 922.4K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $65.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.53 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.11 | $1.65 |
| 52 Week High | $11.23 | $3.19 |
Technical Indicators
Market Signals| Indicator | HLXC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 61.12 |
| Support Level | $10.14 | $2.59 |
| Resistance Level | $10.30 | $3.19 |
| Average True Range (ATR) | 0.02 | 0.16 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 66.67 | 71.74 |
Price Performance
Historical Comparison HLXC
PLX
About HLXC Helix Acquisition Corp. III Class A Ordinary Shares
Helix Acquisition Corp III is a blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.